Compare

Assembly Biosciences Inc./$ASMB

1D1W1M3M6MYTD1Y5YMAX

About Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
Ticker
$ASMB
Sector
Health
Primary listing
NASDAQ
Employees
73
Headquarters
South San Francisco, United States
Website
www.assemblybio.com

ASMB Metrics

BasicAdvanced
$411M
-
-$0.00
1.09
-

What the Analysts think about ASMB

Analyst ratings (Buy, Hold, Sell) for Assembly Biosciences Inc. stock.
Analyst projections of the future price of Assembly Biosciences Inc. stock.

Bulls say / Bears say

ABI-6250 has moved into Phase 2 for hepatitis delta after Phase 1a showed once-daily dosing potential, target engagement and no serious adverse events. Its oral format could be more convenient than injectable options, although patient efficacy is not yet established. (Assembly Biosciences)
Assembly is also advancing ABI-6250 for PBC and PSC, giving the same oral candidate a potential route into additional liver-disease markets. The FDA has allowed the planned Phase 2 study to proceed, with initiation expected in early 2027. (GlobeNewswire)
Gilead is leading GS-1179’s next clinical stage, while Assembly has elected to share 40% of US development costs and profits, retaining meaningful commercial upside. Assembly reported $314.3 million in cash and securities at September-end and said the Gilead payment received in November extends its runway into 2029. (GlobeNewswire)
ABI-6250 remains unproven in patients: its Phase 2 hepatitis delta study has only just begun, with initial data not expected until the fourth quarter of 2027. The programme’s investment case therefore still depends on a future clinical readout. (Assembly Biosciences)
Phase 1a testing found an off-target transporter biomarker increase at the highest tested single dose, alongside self-limited ALT elevations. These findings do not establish a serious safety problem, but they make dose selection and longer-term safety important risks for a drug intended for chronic use. (SEC)
The company remains loss-making, and its third-quarter net loss widened to $20.3 million from $9.2 million a year earlier as research costs rose and collaboration revenue fell. A recent equity financing also substantially increased the weighted-average share count, highlighting dilution risk before any product sales. (GlobeNewswire, SEC)
Data summarised monthly by Lightyear AI. Last updated on 13 Nov 2026.

ASMB Financial Performance

Revenues and expenses
Income statement
AnnuallyQuarterly
2023
YoY growth
Revenue
Net income
Profit margin

ASMB Earnings Performance

Company profitability
Earnings per share
AnnuallyQuarterly
2020
2021
2022
2023
2024
Actual
Expected
Surprise

Funds containing ASMB

Funds
Fund name
Fund size
$ASMB weighting
SPDR Russell 2000 US Small Cap€R2US
$4.7B0.01%
SPDR Russell 2000 US Small Cap£R2SC
$4.7B0.01%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.